Antibody-drug conjugates: Current status and future perspectives

Pharmacology and Therapeutics

Volumn 167, Issue , 2016, Pages 48-59

  Gébleux, Rémy ^a   Casi, Giulio ^b  

^a ETH ZURICH   (Switzerland)

^b Senn Chemicals AG   (Switzerland)

Author keywords

Antibody drug conjugates; Clinical trial; Conjugations; Format; Linkers; Payloads

Indexed keywords

ANTIBODY CONJUGATE; DNA; RNA; TUBULIN; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; CHEMISTRY; DRUG CONJUGATION; INTERNALIZATION; PRECLINICAL STUDY; PRIORITY JOURNAL; ANIMAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; HUMAN; IMMUNOLOGY; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; NEOPLASMS;

EID: 84994057022     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.07.012     Document Type: Article

References (164)

1. Ab, O., Whiteman, K.R., Bartle, L.M., Sun, X.X., Singh, R., Tavares, D.,.. Lambert, J.M., Imgn853, a folate receptor-alpha (fr alpha)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against fr alpha-expressing tumors. Mol Cancer Ther 14 (2015), 1605–1613.
2. Agarwal, P., Kudirka, R., Albers, A.E., Barfield, R.M., de Hart, G.W., Drake, P.M.,.. Rabuka, D., Hydrazino–Pictet–Spengler ligation as a biocompatible method for the generation of stable protein conjugates. Bioconjug Chem 24 (2013), 846–851.
3. Alley, S.C., Benjamin, D.R., Jeffrey, S.C., Okeley, N.M., Meyer, D.L., Sanderson, R.J., Senter, P.D., Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem 19 (2008), 759–765.
4. Alley, S.C., Zhang, X., Okeley, N.M., Anderson, M., Law, C.-L., Senter, P.D., Benjamin, D.R., The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 330 (2009), 932–938.
5. Axup, J.Y., Bajjuri, K.M., Ritland, M., Hutchins, B.M., Kim, C.H., Kazane, S.A.,.. Schultz, P.G., Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A 109 (2012), 16101–16106.
6. Bai, R., Pettit, G.R., Hamel, E., Dolastatin-10, a powerful cytostatic peptide derived from a marine animal — inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39 (1990), 1941–1949.
7. Ballantyne, A., Dhillon, S., Trastuzumab emtansine: first global approval. Drugs 73 (2013), 755–765.
8. Bernardes, G.J.L., Casi, G., Truessel, S., Hartmann, I., Schwager, K., Scheuermann, J., Neri, D., A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed 51 (2012), 941–944.
9. Bernardes, G.J.L., Steiner, M., Hartmann, I., Neri, D., Casi, G., Site-specific chemical modification of antibody fragments using traceless cleavable linkers. Nat Protoc 8 (2013), 2079–2089.
10. Berndorff, D., Borkowski, S., Sieger, S., Rother, A., Friebe, M., Viti, F.,.. Dinkelborg, L.M., Radioimmunotherapy of solid tumors by targeting extra domain b fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res 11 (2005), 7053S–7063S.
11. Bhakta, S., Raab, H., Junutula, J.R., Engineering thiomabs for site-specific conjugation of thiol-reactive linkers. Antibody-Drug Conjugates 1045 (2013), 189–203.
12. Bhattacharyya, B., Wolff, J., Maytansine binding to vinblastine sites of tubulin. FEBS Lett 75 (1977), 159–162.
13. Blanc, V., Bousseau, A., Caron, A., Carrez, C., Lutz, R.J., Lambert, J.M., Sar3419: an anti-cd19-maytansinoid immunoconjugate for the treatment of b-cell malignancies. Clin Cancer Res 17 (2011), 6448–6458.
14. Bodenmiller, B., Multiplexed epitope-based tissue imaging for discovery and healthcare applications. Cell Syst 2 (2016), 225–238.
15. Boger, D.L., Johnson, D.S., Cc-1065 and the duocarmycins — unraveling the keys to a new class of naturally derived dna alkylating-agents. Proc Natl Acad Sci U S A 92 (1995), 3642–3649.
16. Bootz, F., Neri, D., Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discov Today 21 (2016), 180–189.
17. Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A.,.. Zardi, L., Selective targeting of tumoral vasculature: comparison of different formats of an antibody (l19) to the ed-b domain of fibronectin. Int J Cancer 102 (2002), 75–85.
18. Borst, P., Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?. Open Biol, 2, 2012.
19. Buskas, T., Li, Y., Boons, G.J., The immunogenicity of the tumor-associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. Chemistry 10 (2004), 3517–3524.
20. Carter, P., Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1 (2001), 118–129.
21. Carter, P., Smith, L., Ryan, M., Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 11 (2004), 659–687.
22. Casi, G., Huguenin-Dezot, N., Zuberbuehler, K., Scheuermann, J., Neri, D., Site-specific traceless coupling of potent cytotoxic drugs to recombinant antibodies for pharmacodelivery. J Am Chem Soc 134 (2012), 5887–5892.
23. Chari, R.V.J., Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41 (2008), 98–107.
24. Chari, R.V.J., Miller, M.L., Widdison, W.C., Antibody- drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed 53 (2014), 3796–3827.
25. Clark, M.A., Selecting chemicals: the emerging utility of DNA-encoded libraries. Curr Opin Chem Biol 14 (2010), 396–403.
26. Cohen, R., Vugts, D.J., Visser, G.W., Stigter-van Walsum, M., Bolijn, M., Spiga, M.,.. van Dongen, G.A., Development of novel adcs: conjugation of tubulysin analogs to trastuzumab monitored by dual radiolabeling. Cancer Res, 2014.
27. Cooper, N., Hagan, D.R., Tiberghien, A., Ademefun, T., Matthews, C.S., Howard, P.W., Thurston, D.E., Synthesis of novel c2-aryl pyrrolobenzodiazepines (pbds) as potential antitumour agents. Chem Commun, 2002, 1764–1765.
28. de Claro, R.A., McGinn, K., Kwitkowski, V., Bullock, J., Khandelwal, A., Habtemariam, B.,.. Pazdur, R., U.S. food and drug administration approval summary: brentuximab vedotin for the treatment of relapsed hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 18 (2012), 5845–5849.
29. Dennis, M.S., Jin, H., Dugger, D., Yang, R., McFarland, L., Ogasawara, A.,.. Schwall, R., Imaging tumors with an albumin-binding fab, a novel tumor-targeting agent. Cancer Res 67 (2007), 254–261.
30. Doronina, S.O., Mendelsohn, B.A., Bovee, T.D., Cerveny, C.G., Alley, S.C., Meyer, D.L.,.. Senter, P.D., Enhanced activity of monomethylauristatin f through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17 (2006), 114–124.
31. Doronina, S.O., Toki, B.E., Torgov, M.Y., Mendelsohn, B.A., Cerveny, C.G., Chace, D.F.,.. Senter, P.D., Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21 (2003), 778–784.
32. Drake, P.M., Albers, A.E., Baker, J., Banas, S., Barfield, R.M., Bhat, A.S.,.. Rabuka, D., Aldehyde tag coupled with hips chemistry enables the production of adcs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and pk outcomes. Bioconjug Chem 25 (2014), 1331–1341.
33. Dubowchik, G.M., Walker, M.A., Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 83 (1999), 67–123.
34. Ellestad, G.A., Structural and conformational features relevant to the anti-tumor activity of calicheamicin gamma(i)(1). Chirality 23 (2011), 660–671.
35. Ellis, P.A., Barrios, C.H., Eiermann, W., Toi, M., Im, Y.-H., Conte, P.F.,.. Perez, E.A., Phase iii, randomized study of trastuzumab emtansine (t-dm1) {+/−} pertuzumab (p) vs trastuzumab + taxane (ht) for first-line treatment of her2-positive mbc: primary results from the marianne study. ASCO Meet Abstr, 33, 2015, 507.
36. Erba, P.A., Sollini, M., Orciuolo, E., Traino, C., Petrini, M., Paganelli, G.,.. Mariani, G., Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies. J Nucl Med 53 (2012), 922–927.
37. Erickson, H.K., Park, P.U., Widdison, W.C., Kovtun, Y.V., Garrett, L.M., Hoffman, K.,.. Blattler, W.A., Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66 (2006), 4426–4433.
38. Erickson, H.K., Widdison, W.C., Mayo, M.F., Whiteman, K., Audette, C., Wilhelm, S.D., Singh, R., Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21 (2010), 84–92.
39. Franzini, R.M., Neri, D., Scheuermann, J., DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries. Acc Chem Res 47 (2014), 1247–1255.
40. Fujiwara, A., Hoshino, T., Anthracycline antibiotics. CRC Crit Rev Biotechnol 3 (1986), 133–157.
41. Gebleux, R., Wulhfard, S., Casi, G., Neri, D., Antibody format and drug release rate determine the therapeutic activity of noninternalizing antibody-drug conjugates. Mol Cancer Ther 14 (2015), 2606–2612.
42. Gébleux, R., Stringhini, M., Casanova, R., Soltermann, A., Neri, D., Manuscript Submitted. 2016.
43. Gerber, H.P., Sapra, P., Loganzo, F., May, C., Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect?. Biochem Pharmacol 102 (2016), 1–6.
44. Ghose, T., Blair, A.H., Antibody-linked cytotoxic agents in treatment of cancer - current status and future prospects. J Natl Cancer Inst 61 (1978), 657–676.
45. Gurcan, H.M., Keskin, D.B., Stern, J.N.H., Nitzberg, M.A., Shekhani, H., Ahmed, A.R., A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9 (2009), 10–25.
46. Gutbrodt, K.L., Casi, G., Neri, D., Antibody-based delivery of il2 and cytotoxics eradicates tumors in immunocompetent mice. Mol Cancer Ther 13 (2014), 1772–1776.
47. Gutbrodt, K.L., Schliemann, C., Giovannoni, L., Frey, K., Pabst, T., Klapper, W.,.. Neri, D., Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med, 5, 2013.
48. Hamann, P.R., Chapter 5 the genesis of the antibody conjugate gemtuzumab ozogamicin (mylotarg[registered sign]) for acute myeloid leukemia. Accounts in Drug Discovery: Case Studies in Medicinal Chemistry, 2011, The Royal Society of Chemistry, 103–119.
49. Hamann, P.R., Hinman, L.M., Hollander, I., Beyer, C.F., Lindh, D., Holcomb, R.,.. Bernstein, I., Gemtuzumab ozogamicin, a potent and selective anti-cd33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13 (2002), 47–58.
50. Hamblett, K.J., Senter, P.D., Chace, D.F., Sun, M.M.C., Lenox, J., Cerveny, C.G.,.. Francisco, J.A., Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10 (2004), 7063–7070.
51. Hartley, J.A., Hamaguchi, A., Coffils, M., Martin, C.R.H., Suggitt, M., Chen, Z.,.. Howard, P.W., Sg2285, a novel c2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity. Cancer Res 70 (2010), 6849–6858.
52. Hemmerle, T., Probst, P., Giovannoni, L., Green, A.J., Meyer, T., Neri, D., The antibody-based targeted delivery of tnf in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Br J Cancer 109 (2013), 1206–1213.
53. Hess, C., Venetz, D., Neri, D., Emerging classes of armed antibody therapeutics against cancer. Med Chem Commun 5 (2014), 408–431.
54. Heuveling, D.A., de Bree, R., Vugts, D.J., Huisman, M.C., Giovannoni, L., Hoekstra, O.S.,.. van Dongen, G.A.M.S., Phase 0 microdosing pet study using the human mini antibody f16sip in head and neck cancer patients. J Nucl Med 54 (2013), 397–401.
55. Huhalov, A., Chester, K.A., Engineered single chain antibody fragments for radioimmunotherapy. Q J Nucl Med Mol Imaging 48 (2004), 279–288.
56. Jain, R.K., Physiological barriers to delivery of monoclonal-antibodies and other macromolecules in tumors. Cancer Res 50 (1990), S814–S819.
57. Jan Anderl, C.M., Heckl-Östreicher, B., Wehr, R., Highly potent antibodyamanitin conjugates cause tumor-selective apoptosis. Cancer Res, 71(78, Supplement 71), 2011.
58. Jeffrey, S.C., Burke, P.J., Lyon, R.P., Meyer, D.W., Sussman, D., Anderson, M.,.. Senter, P.D., A potent anti-cd70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 24 (2013), 1256–1263.
59. Jeger, S., Zimmermann, K., Blanc, A., Grunberg, J., Honer, M., Hunziker, P.,.. Schibli, R., Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem Int Ed Engl 49 (2010), 9995–9997.
60. Junutula, J.R., Flagella, K.M., Graham, R.A., Parsons, K.L., Ha, E., Raab, H.,.. Sliwkowski, M.X., Engineered thio-trastuzumab-dm1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res 16 (2010), 4769–4778.
61. Junutula, J.R., Raab, H., Clark, S., Bhakta, S., Leipold, D.D., Weir, S.,.. Mallet, W., Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26 (2008), 925–932.
62. Kang, Y.-K., Shah, M.A., Ohtsu, A., Van Cutsem, E., Ajani, J.A., van der Horst, T.,.. Thuss-Patience, P.C., A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (t-dm1) versus a taxane (tax) in patients (pts) with previously treated her2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (la/mgc/gejc). ASCO Meet Abstr, 34, 2016, 5.
63. Kantarjian, H., Thomas, D., Jorgensen, J., Jabbour, E., Kebriaei, P., Rytting, M.,.. O'Brien, S., Inotuzumab ozogamicin, an anti-cd22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13 (2012), 403–411.
64. Kellner, C., Derer, S., Valerius, T., Peipp, M., Boosting adcc and cdc activity by fc engineering and evaluation of antibody effector functions. Methods 65 (2014), 105–113.
65. Kellogg, B.A., Garrett, L., Kovtun, Y., Lai, K.C., Leece, B., Miller, M.,.. Lutz, R.J., Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 22 (2011), 717–727.
66. Kelly, K.R., Chanan-Khan, A., Somlo, G., Heffner, L.T., Siegel, D.S., Zimmerman, T.M.,.. Anderson, K.C., Indatuximab ravtansine (bt062) in combination with lenalidomide and low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma: clinical activity in len/dex-refractory patients. Blood, 122, 2013.
67. Kim, C.H., Axup, J.Y., Schultz, P.G., Protein conjugation with genetically encoded unnatural amino acids. Curr Opin Chem Biol 17 (2013), 412–419.
68. Knowles, S.M., Wu, A.M., Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. J Clin Oncol 30 (2012), 3884–3892.
69. Kovtun, Y.V., Audette, C.A., Mayo, M.F., Jones, G.E., Doherty, H., Maloney, E.K.,.. Chari, R.V.J., Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 70 (2010), 2528–2537.
70. Kovtun, Y.V., Audette, C.A., Ye, Y.M., Xie, H.S., Ruberti, M.F., Phinney, S.J.,.. Goldmacher, V.S., Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66 (2006), 3214–3221.
71. Kovtun, Y.V., Goldmacher, V.S., Cell killing by antibody-drug conjugates. Cancer Lett 255 (2007), 232–240.
72. Krall, N., Scheuermann, J., Neri, D., Small targeted cytotoxics: current state and promises from DNA-encoded chemical libraries. Angew Chem Int Ed 52 (2013), 1384–1402.
73. Krop, I., Winer, E.P., Trastuzumab emtansine: a novel antibody-drug conjugate for her2-positive breast cancer. Clin Cancer Res 20 (2014), 15–20.
74. Kung Sutherland, M.S., Walter, R.B., Jeffrey, S.C., Burke, P.J., Yu, C., Kostner, H.,.. McEarchern, J.A., Sgn-cd33a: a novel cd33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant aml. Blood 122 (2013), 1455–1463.
75. Lambert, J.M., Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 76 (2013), 248–262.
76. Lambert, J.M., Chari, R.V., Ado-trastuzumab emtansine (t-dm1): an antibody-drug conjugate (adc) for her2-positive breast cancer. J Med Chem 57 (2014), 6949–6964.
77. Lang, K., Chin, J.W., Cellular incorporation of unnatural amino acids and bioorthogonal labeling of proteins. Chem Rev 114 (2014), 4764–4806.
78. Larson, S.M., Carrasquillo, J.A., Cheung, N.K.V., Press, O.W., Radioimmunotherapy of human tumours. Nat Rev Cancer 15 (2015), 347–360.
79. Laszlo, G.S., Estey, E.H., Walter, R.B., The past and future of cd33 as therapeutic target in acute myeloid leukemia. Blood Rev 28 (2014), 143–153.
80. Lee, F.T., Hall, C., Rigopoulos, A., Zweit, J., Pathmaraj, K., O'Keefe, G.J.,.. Scott, A.M., Immuno-pet of human colon xenograft- bearing balb/c nude mice using 124i-cdr-grafted humanized a33 monoclonal antibody. J Nucl Med 42 (2001), 764–769.
81. Lee, M.D., Dunne, T.S., Chang, C.C., Ellestad, G.A., Siegel, M.M., Morton, G.O.,.. Borders, D.B., Calichemicins, a novel family of antitumor antibiotics.2. Chemistry and structure of calichemicin-gamma-1. J Am Chem Soc 109 (1987), 3466–3468.
82. Lee, M.D., Dunne, T.S., Siegel, M.M., Chang, C.C., Morton, G.O., Borders, D.B., Calichemicins, a novel family of antitumor antibiotics.1. Chemistry and partial structure of calichemicin-gamma-1. J Am Chem Soc 109 (1987), 3464–3466.
83. Lhospice, F., Bregeon, D., Belmant, C., Dennler, P., Chiotellis, A., Fischer, E.,.. Romagne, F., Site-specific conjugation of monomethyl auristatin e to anti-cd30 antibodies improves their pharmacokinetics and therapeutic index in rodent models. Mol Pharm 12 (2015), 1863–1871.
84. Liebscher, S., Schopfel, M., Aumuller, T., Sharkhuukhen, A., Pech, A., Hoss, E.,.. Bordusa, F., N-terminal protein modification by substrate-activated reverse proteolysis. Angew Chem Int Ed Engl 53 (2014), 3024–3028.
85. Lindell, T.J., Weinberg, F., Morris, P.W., Roeder, R.G., Rutter, W.J., Specific inhibition of nuclear rna polymerase ii by alpha-amanitin. Science, 170, 1970 (447-&).
86. List, T., Casi, G., Neri, D., A chemically defined trifunctional antibody-cytokine-drug conjugate with potent antitumor activity. Mol Cancer Ther 13 (2014), 2641–2652.
87. List, T., Neri, D., Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol 5 (2013), 29–45.
88. Litovchick, A., Dumelin, C.E., Habeshian, S., Gikunju, D., Guie, M.A., Centrella, P.,.. Clark, M.A., Encoded library synthesis using chemical ligation and the discovery of seh inhibitors from a 334-million member library. Sci Rep, 5, 2015, 10916.
89. Lyon, R.P., Bovee, T.D., Doronina, S.O., Burke, P.J., Hunter, J.H., Neff-LaFord, H.D.,.. Senter, P.D., Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat Biotechnol 33 (2015), 733–735.
90. Lyon, R.P., Setter, J.R., Bovee, T.D., Doronina, S.O., Hunter, J.H., Anderson, M.E.,.. Senter, P.D., Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates. Nat Biotechnol 32 (2014), 1059–1062.
91. Madej, M.P., Coia, G., Williams, C.C., Caine, J.M., Pearce, L.A., Attwood, R.,.. Adams, T.E., Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by sortase a-mediated protein ligation. Biotechnol Bioeng 109 (2012), 1461–1470.
92. McDonagh, C.F., Turcott, E., Westendorf, L., Webster, J.B., Alley, S.C., Kim, K.,.. Carter, P., Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 19 (2006), 299–307.
93. Mills, B.J., Lang, C.A., Differential distribution of free and bound glutathione and cyst(e)Ine in human blood. Biochem Pharmacol 52 (1996), 401–406.
94. Moldenhauer, G., Salnikov, A.V., Luettgau, S., Herr, I., Anderl, J., Faulstich, H., Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma. J Natl Cancer Inst 104 (2012), 622–634.
95. Mullard, A., Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 12 (2013), 329–333.
96. Muller, P., Kreuzaler, M., Khan, T., Thommen, D.S., Martin, K., Glatz, K.,.. Zippelius, A., Trastuzumab emtansine (t-dm1) renders her2 + breast cancer highly susceptible to ctla-4/pd-1 blockade. Sci Transl Med, 7, 2015, 315ra188.
97. Naumovski, L., Junutula, J.R., Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein b mab and monomethyl auristatin e for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 12 (2010), 248–257.
98. Neri, D., Bicknell, R., Tumour vascular targeting. Nat Rev Cancer 5 (2005), 436–446.
99. Neri, D., Sondel, P.M., Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol 40 (2016), 96–102.
100. Neri, D., Zardi, L., Affinity reagents against tumour-associated extracellular molecules and newforming vessels. Adv Drug Deliv Rev 31 (1998), 43–52.
101. Nolting, B., Linker technologies for antibody-drug conjugates. Methods Mol Biol 1045 (2013), 71–100.
102. Owonikoko, T.K., Hussain, A., Stadler, W.M., Smith, D.C., Kluger, H., Molina, A.M.,.. Cohen, L.J., First-in-human multicenter phase I study of bms-936561 (mdx-1203), an antibody-drug conjugate targeting cd70. Cancer Chemother Pharmacol 77 (2016), 155–162.
103. Palumbo, A., Hauler, F., Dziunycz, P., Schwager, K., Soltermann, A., Pretto, F.,.. Neri, D., A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer 104 (2011), 1106–1115.
104. Panowksi, S., Bhakta, S., Raab, H., Polakis, P., Junutula, J.R., Site-specific antibody drug conjugates for cancer therapy. MAbs 6 (2014), 34–45.
105. Parry, R.V., Chemnitz, J.M., Frauwirth, K.A., Lanfranco, A.R., Braunstein, I., Kobayashi, S.V.,.. Riley, J.L., Ctla-4 and pd-1 receptors inhibit t-cell activation by distinct mechanisms. Mol Cell Biol 25 (2005), 9543–9553.
106. Pasche, N., Neri, D., Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 17 (2012), 583–590.
107. Perrino, E., Steiner, M., Krall, N., Bernardes, G.J., Pretto, F., Casi, G., Neri, D., Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res 74 (2014), 2569–2578.
108. Petrylak, D., Kantoff, P., Mega, A., Stephenson, J., Vogelzang, N., Fleming, M.,.. Israel, R.J., Prostate specific membrane antigen antibody drug conjugate (psma adc): a phase 1 trial in castration-resistant metastatic prostate cancer (mcrpc). Eur J Cancer, 48, 2012, 75.
109. Petrylak, D.P., Smith, D.C., Appleman, L.J., Fleming, M.T., Hussain, A., Dreicer, R.,.. Israel, R.J., A phase ii trial of prostate-specific membrane antigen antibody drug conjugate (psma adc) in taxane-refractory metastatic castration-resistant prostate cancer (mcrpc). J Clin Oncol, 32, 2014.
110. Poli, G.L., Bianchi, C., Virotta, G., Bettini, A., Moretti, R., Trachsel, E.,.. Bruno, A., Radretumab radioimmunotherapy in patients with brain metastasis: a i-124-l19sip dosimetric pet study. Cancer Immunol Res 1 (2013), 134–143.
111. Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J Clin Oncol, 33, 2015 (1974-U1161).
112. Rabuka, D., Rush, J.S., deHart, G.W., Wu, P., Bertozzi, C.R., Site-specific chemical protein conjugation using genetically encoded aldehyde tags. Nat Protoc 7 (2012), 1052–1067.
113. Ribrag, V., Dupuis, J., Tilly, H., Morschhauser, F., Laine, F., Houot, R.,.. Coiffier, B., A dose-escalation study of sar3419, an anti-cd19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory b-cell non-hodgkin lymphoma. Clin Cancer Res 20 (2014), 213–220.
114. Ritchie, M., Tchistiakova, L., Scott, N., Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs 5 (2013), 13–21.
115. Robinson, M.K., Doss, M., Shaller, C., Narayanan, D., Marks, J.D., Adler, L.P.,.. Adams, G.P., Quantitative immuno-positron emission tomography imaging oil her2-positive tumor xenografts with an iodine-124 labeled anti-her2 diabody. Cancer Res 65 (2005), 1471–1478.
116. Rothberg, J.M., Bailey, K.M., Wojtkowiak, J.W., Ben-Nun, Y., Bogyo, M., Weber, E.,.. Sloane, B.F., Acid-mediated tumor proteolysis: contribution of cysteine cathepsins. Neoplasia 15 (2013), 1111–1123.
117. Rudnick, S.I., Lou, J., Shaller, C.C., Tang, Y., Klein-Szanto, A.J.P., Weiner, L.M.,.. Adams, G.P., Influence of affinity and antigen internalization on the uptake and penetration of anti-her2 antibodies in solid tumors. Cancer Res 71 (2011), 2250–2259.
118. Rytting, M., Triche, L., Thomas, D., O'Brien, S., Kantarjian, H., Initial experience with cmc-544 (inotuzumab ozogamicin) in pediatric patients with relapsed b-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 61 (2014), 369–372.
119. Saleh, M.N., Sugarman, S., Murray, J., Ostroff, J.B., Healey, D., Jones, D.,.. LoBuglio, A.F., Phase i trial of the anti-Lewis y drug immunoconjugate br96-doxorubicin in patients with Lewis y-expressing epithelial tumors. J Clin Oncol 18 (2000), 2282–2292.
120. Schliemann, C., Gutbrodt, K.L., Kerkhoff, A., Pohlen, M., Wiebe, S., Silling, G.,.. Berdel, W.E., Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Res 3 (2015), 547–556.
121. Schliemann, C., Wiedmer, A., Pedretti, M., Szczepanowski, M., Klapper, W., Neri, D., Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-c isoforms in human lymphoma. Leuk Res 33 (2009), 1718–1722.
122. Schmidt, M.M., Wittrup, K.D., A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8 (2009), 2861–2871.
123. Schwager, K., Villa, A., Roesli, C., Neri, D., Roesli-Khabas, M., Moser, G., A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol, 3, 2011.
124. Sedlacek, H.H., Antibodies as Carriers of Cytotoxicity. 1992, Karger, Basel; New York.
125. Senter, P.D., Sievers, E.L., The discovery and development of brentuximab vedotin for use in relapsed hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol 30 (2012), 631–637.
126. Sharkey, R.M., Hajjar, G., Yeldell, D., Brenner, A., Burton, J., Rubin, A., Goldenberg, D.M., A phase I trial combining high-dose y-90-labeled humanized anti-cea monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer. J Nucl Med 46 (2005), 620–633.
127. Shen, B.Q., Xu, K.Y., Liu, L.N., Raab, H., Bhakta, S., Kenrick, M.,.. Junutula, J.R., Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 30 (2012), 184–189.
128. Sletten, E.M., Bertozzi, C.R., From mechanism to mouse: a tale of two bioorthogonal reactions. Acc Chem Res 44 (2011), 666–676.
129. Srinivasarao, M., Galliford, C.V., Low, P.S., Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat Rev Drug Discov 14 (2015), 203–219.
130. Stein, R., Smith, M.R., Chen, S., Zalath, M., Goldenberg, D.M., Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin Cancer Res 15 (2009), 2808–2817.
131. Stillebroer, A.B., Zegers, C.M., Boerman, O.C., Oosterwijk, E., Mulders, P.F., O'Donoghue, J.A.,.. Oyen, W.J., Dosimetric analysis of 177lu-cg250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111in-cg250 imaging. J Nucl Med 53 (2012), 82–89.
132. Strassberger, V., Fugmann, T., Neri, D., Roesli, C., Chemical proteomic and bioinformatic strategies for the identification and quantification of vascular antigens in cancer. J Proteome 73 (2010), 1954–1973.
133. Strop, P., Delaria, K., Foletti, D., Witt, J.M., Hasa-Moreno, A., Poulsen, K.,.. Rajpal, A., Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol 33 (2015), 694–696.
134. Strop, P., Liu, S.H., Dorywalska, M., Delaria, K., Dushin, R.G., Tran, T.T.,.. Rajpal, A., Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem Biol 20 (2013), 161–167.
135. Sun, M.M.C., Beam, K.S., Cerveny, C.G., Hamblett, K.J., Blackmore, R.S., Torgov, M.Y.,.. Alley, S.C., Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16 (2005), 1282–1290.
136. Sun, X.X., Widdison, W., Mayo, M., Wilhelm, S., Leece, B., Chari, R.,.. Erickson, H., Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 22 (2011), 728–735.
137. Szakacs, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C., Gottesman, M.M., Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5 (2006), 219–234.
138. Takahashi, I., Takahashi, K., Ichimura, M., Morimoto, M., Asano, K., Kawamoto, I.,.. Nakano, H., Duocarmycin-a, a new antitumor antibiotic from streptomyces. J Antibiot 41 (1988), 1915–1917.
139. Tamura, K., Kurihara, H., Yonemori, K., Tsuda, H., Suzuki, J., Kono, Y.,.. Fujiwara, Y., Cu-64-dota-trastuzumab pet imaging in patients with her2-positive breast cancer. J Nucl Med 54 (2013), 1869–1875.
140. Tannir, N.M., Forero-Torres, A., Ramchandren, R., Pal, S.K., Ansell, S.M., Infante, J.R.,.. Thompson, J.A., Phase i dose-escalation study of sgn-75 in patients with cd70-positive relapsed/refractory non-hodgkin lymphoma or metastatic renal cell carcinoma. Investig New Drugs 32 (2014), 1246–1257.
141. Teicher, B.A., Chari, R.V.J., Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 17 (2011), 6389–6397.
142. Terrett, J., Gangwar, S., Rao-Naik, C., Pan, C., Guerlavais, V., Huber, M.,.. Sattari, P., Single, low dose treatment of lymphoma and renal cancer xenografts with human anti-cd70 antibody-toxin conjugates, results in long term cures. Cancer Res, 67, 2007, 4112.
143. Thorpe, P.E., Wallace, P.M., Knowles, P.P., Relf, M.G., Brown, A.N.F., Watson, G.J.,.. Blakey, D.C., New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability invivo. Cancer Res 47 (1987), 5924–5931.
144. Tian, F., Lu, Y., Manibusan, A., Sellers, A., Tran, H., Sun, Y.,.. Sapra, P., A general approach to site-specific antibody drug conjugates. Proc Natl Acad Sci U S A 111 (2014), 1766–1771.
145. Tolcher, A.W., Sugarman, S., Gelmon, K.A., Cohen, R., Saleh, M., Isaacs, C.,.. Slichenmyer, W., Randomized phase ii study of br96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol 17 (1999), 478–484.
146. Trail, P.A., Willner, D., Lasch, S.J., Henderson, A.J., Hofstead, S., Casazza, A.M.,.. Hellstrom, K.E., Cure of xenografted human carcinomas by br96-doxorubicin immunoconjugates. Science 261 (1993), 212–215.
147. van der Lee, M.M., Groothuis, P.G., Ubink, R., van der Vleuten, M.A., van Achterberg, T.A., Loosveld, E.M.,.. Dokter, W.H., The preclinical profile of the duocarmycin-based her2-targeting adc syd985 predicts for clinical benefit in low her2-expressing breast cancers. Mol Cancer Ther, 2015.
148. van der Velden, V.H.J., te Mervelde, J.G., Hoogeveen, P.G., Bernstein, I.D., Houtsmuller, A.B., Berger, M.S., van Dongen, J.J.M., Targeting of the cd33-calicheamicin immunoconjugate mylotarg (cma-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 97 (2001), 3197–3204.
149. van der Veldt, A.A.M., Hendrikse, N.H., Smit, E.F., Mooijer, M.P.J., Rijnders, A.Y., Gerritsen, W.R.,.. Lubberink, M., Biodistribution and radiation dosimetry of c-11-labelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging 37 (2010), 1950–1958.
150. van der Veldt, A.A.M., Lubberink, M., Mathijssen, R.H.J., Loos, W.J., Herder, G.J.M., Greuter, H.N.,.. Lammertsma, A.A., Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using c-11 docetaxel and positron emission tomography. Clin Cancer Res 19 (2013), 4163–4173.
151. Vater, C.A., Goldmacher, V.S., Antibody-cytotoxic compound conjugates for oncology. Macromol Anticancer Ther, 2010, 331–369.
152. Walker, S., Landovitz, R., Ding, W.D., Ellestad, G.A., Kahne, D., Cleavage behavior of calicheamicin gamma-1 and calicheamicin-t. Proc Natl Acad Sci U S A 89 (1992), 4608–4612.
153. Wall, M.E., Wani, M.C., Cook, C.E., Palmer, K.H., Mcphail, A.T., Sim, G.A., Plant antitumor agents.I. Isolation and structure of camptothecin a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88 (1966), 3888–3890.
154. Wang, L.T., Amphlett, G., Blattler, W.A., Lambert, J.M., Zhang, W., Structural characterization of the maytansinoid — monoclonal antibody immunoconjugate, hun901-dm1, by mass spectrometry. Protein Sci 14 (2005), 2436–2446.
155. Wang, X.N., Ma, D.S., Olson, W.C., Heston, W.D.W., In vitro and in vivo responses of advanced prostate tumors to psma adc, an auristatin-conjugated antibody to prostate-specific membrane antigen. Mol Cancer Ther 10 (2011), 1728–1739.
156. Winter, G., Griffiths, A.D., Hawkins, R.E., Hoogenboom, H.R., Making antibodies by phage display technology. Annu Rev Immunol 12 (1994), 433–455.
157. Wong, J.Y., Thomas, G.E., Yamauchi, D., Williams, L.E., Odom-Maryon, T.L., Liu, A.,.. Raubitschek, A.A., Clinical evaluation of indium-111-labeled chimeric anti-cea monoclonal antibody. J Nucl Med 38 (1997), 1951–1959.
158. Wu, A.M., Senter, P.D., Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23 (2005), 1137–1146.
159. Wu, G.Y., Fang, Y.Z., Yang, S., Lupton, J.R., Turner, N.D., Glutathione metabolism and its implications for health. J Nutr 134 (2004), 489–492.
160. Ychou, M., Pelegrin, A., Faurous, P., Robert, B., Saccavini, J.C., Guerreau, D.,.. Artus, J.C., Phase-i/ii radio-immunotherapy study with iodine-131-labeled anti-cea monoclonal antibody f6 f(ab′)(2) in patients with non-resectable liver metastases from colorectal cancer. Int J Cancer 75 (1998), 615–619.
161. Yoshikawa, M., Mukai, Y., Okada, Y., Tsumori, Y., Tsunoda, S., Tsutsumi, Y.,.. Nakagawa, S., Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-robo4 cell-internalizing antibody. Blood 121 (2013), 2804–2813.
162. Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial, S.D., Kwak, L.W.,.. Gordon, L.I., Phase i multidose-escalation study of the anti-cd19 maytansinoid immunoconjugate sar3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory b-cell lymphoma. J Clin Oncol 30 (2012), 2776–2782.
163. Yu, S.F., Zheng, B., Go, M., Lau, J., Spencer, S., Raab, H.,.. Polson, A.G., A novel anti-cd22 anthracycline-based antibody-drug conjugate (adc) that overcomes resistance to auristatin-based adcs. Clin Cancer Res 21 (2015), 3298–3306.
164. Zuberbuhler, K., Casi, G., Bernardes, G.J., Neri, D., Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in igg format. Chem Commun (Camb) 48 (2012), 7100–7102.